A federal appeals court today again upheld its decision to award a win to NuVasive Inc. (NSDQ:NUVA) in 1 of its long-running patent infringement battles with spine implant rival Medtronic (NYSE:MDT).
The U.S. Supreme Court in January remanded the case back to the U.S. Court of Appeals for the Federal Circuit, after deciding last year that a defendant’s belief regarding patent validity is not a defense to an induced infringement claim.
Medtronic had asked the U.S. Supreme Court to review the Federal Circuit decision; the high court ordered the appeals court to reconsider the case in light of its May 2015 decision in Commil v. Cisco.
Medtronic, in a June 2015 certiorari filing with the Supreme Court, had argued that the Commil decision also applies to the NuVasive beef.
“There is not a shred of evidence that Medtronic knew surgeons using its NIM-Eclipse medical device during spinal surgery would infringe NuVasive’s patent. Quite the opposite,” the company claimed last year. “Since 1st learning of NuVasive’s patent, Medtronic reasonable believed using its NIM-Eclipse device during surgery did not infringe under a proper reading of the patent claims.”
Today the Federal Circuit once again sided with NuVasive and reinstated its earlier finding for damages, according to court documents.
“[Medtronic’s] knowledge of the ‘236 patent is undisputed. As such, under these circumstances, a reasonable jury could have concluded that [Medtronic’s] non-infringement position was objectively unreasonable and that [Medtronic] must have known that NIM-Eclipse meets the limitations of the claims of the ‘236 patent. A reasonable jury could therefore have inferred that MSD must have known, or was willfully blind to the fact, that doctors using the device infringe those claims,” the appeals court ruled.
The post Appeals court again upholds NuVasive in patent win over Medtronic appeared first on MassDevice.